HC Wainwright Issues Pessimistic Forecast for YMAB Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Equities research analysts at HC Wainwright reduced their Q2 2025 earnings estimates for shares of Y-mAbs Therapeutics in a research report issued on Monday, May 19th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.23) per share for the quarter, down from their […]

Leave a Reply

Your email address will not be published.

Previous post Equities Analysts Issue Forecasts for SVC Q2 Earnings
Next post HC Wainwright Estimates RenovoRx’s Q2 Earnings (NASDAQ:RNXT)